Jonathan Lovell
@jflovell.bsky.social
SUNY Buffalo Biomedical Engineering. Western New York and Niagara.
Reposted by Jonathan Lovell
May 4, 2025 at 2:39 PM
Reposted by Jonathan Lovell
GOOD NEWS! Researchers at the University of Buffalo have developed a nanoparticle-based vaccine candidate for H5N1 avian influenza (clade 2.3.4.4b) that achieved 100% PROTECTION in preclinical trials. The vaccine is under development for potential use in BOTH veterinary AND human medicine. 🧪🧵⬇️
April 22, 2025 at 4:00 PM
GOOD NEWS! Researchers at the University of Buffalo have developed a nanoparticle-based vaccine candidate for H5N1 avian influenza (clade 2.3.4.4b) that achieved 100% PROTECTION in preclinical trials. The vaccine is under development for potential use in BOTH veterinary AND human medicine. 🧪🧵⬇️
Reposted by Jonathan Lovell
Highly pathogenic avian influenza H5N1 clade 2.3.4.4b hemagglutinin and/or neuraminidase elicit immunity in a recombinant nanoparticle vaccine: Cell Biomaterials www.cell.com/cell-biomate...
Highly pathogenic avian influenza H5N1 clade 2.3.4.4b hemagglutinin and/or neuraminidase elicit immunity in a recombinant nanoparticle vaccine
CoPoP liposomes enable facile display of recombinant H5 and N1 derived from highly
pathogenic avian influenza (HPAI), H5N1 clade 2.3.4.4b. With vaccination, mice elicited
functional antibody responses...
www.cell.com
April 19, 2025 at 1:35 AM
Highly pathogenic avian influenza H5N1 clade 2.3.4.4b hemagglutinin and/or neuraminidase elicit immunity in a recombinant nanoparticle vaccine: Cell Biomaterials www.cell.com/cell-biomate...